DL-AP5 (lithium)

DL-AP5 (lithium)

• CAS Number: 125229-62-1
• UNSPSC Description: DL-AP5 (2-APV) lithium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 lithium shows significantly antinociceptive activity. DL-AP5 lithium specifically blocks on channels in the rabbit retina[1][2][3].
• Target Antigen: iGluR
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling
• Field of Research: Inflammation/Immunology; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/dl-ap5-lithium.html
• Solubility: 10 mM in DMSO
• Smiles: NC(CCCP(O)(O)=O)C(O[Li])=O
• Molecular Weight: 203.06
• References & Citations: [1]Murray CW, et al. Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model. Pain. 1991;44(2):179-185.|[2]Massey SC, et al. N-methyl-D-aspartate receptors of ganglion cells in rabbit retina. J Neurophysiol. 1990;63(1):16-30.|[3]Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res. 2006 Apr 25;169(1):120-7.|[4]Taati M, et al. The effects of DL-AP5 and glutamate on ghrelin-induced feeding behavior in 3-h food-deprived broiler cockerels. J Physiol Biochem. 2011 Jun;67(2):217-23.|[5]Chen T, et al. Glutamate-induced rapid induction of Arc/Arg3.1 requires NMDA receptor-mediated phosphorylation of ERK and CREB. Neurosci Lett. 2017 Nov 20;661:23-28.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported